(See irstructlons); In this competing renewal P01 application, the Administrative Core will continue to provide centralized grant administration, communication processing, and budget management This Core will also serve to amalgamate the investigators, their experimental findings and their ideas, evaluation of research efforts and also to direct the summary efforts toward the Program outcome.
The Specific Aims of the Administrative Core include the following: 1. Provide administrative services to the investigators. This includes the management of project supplies, filing, development of memos, meeting minutes and communications covering all operations, including publications. 2. Organize monthly meetings of the Program Steering Committee to facilitate effective communication and decision making to ensure scientific progress of the Program. 3. Organize an annual External/Internal Scientific Advisory Board meeting. The External and Internal Scientific Advisory Board shall review all experimental findings and clinical outcomes, help prioritize investigations, review the coordination of collaborations, and evaluate concepts that emerge from the studies. 4. Maintain program integration activities. This includes data sharing, rapid publication efforts, and identify and institute other novel activities critical to maintaining and strengthening the integration of the program. 5. Provide overall fiscal review, accounting, and real time budget analyses. This includes reports, verbal communications, reviews and forward-looking projections on expenditures.

Public Health Relevance

The Administrative Core is essential for the functions of the Program as an engine for discovery in the human innate immune system and for translating these basic discoveries into rational immunotherapy for the treatment of human cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095426-12
Application #
8563849
Study Section
Special Emphasis Panel (ZCA1-RPRB-B)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
12
Fiscal Year
2013
Total Cost
$149,512
Indirect Cost
$94,125
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539

Showing the most recent 10 out of 294 publications